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Abstract
Objective: SerpinA1 (alpha-1 antitrypsin) is an acute inflammatory protein,
which seems to play a role in neurodegeneration and neuroinflammation. In
Alzheimer’s disease and synucleinopathies, SerpinA1 is overexpressed in the
brain and the cerebrospinal fluid (CSF) showing abnormal patterns of its
charge isoforms. To date, no comprehensive studies explored SerpinA1 CSF iso-
forms in Creutzfeldt–Jakob disease (CJD) and frontotemporal lobar degenera-
tion (FTLD). Methods: Using a capillary isoelectric focusing immunoassay, we
analyzed CSF SerpinA1 isoforms in control cases (n = 31) and patients with a
definite or probable diagnosis of CJD (n=77) or FTLD (n = 30), belonging to
several disease subtypes. Results: The overall SerpinA1 signal was significantly
higher than in controls in CJD subtypes linked to abnormal prion protein
(PrPSc) type 1, such as sporadic CJD (sCJD) MM(V)1, and in FTLD-TDP.
Moreover, CJD linked to PrPSc type 1 and FTLD-TAU groups showed a signifi-
cant relative increase of acidic and basic isoforms in comparison with controls,
thereby forming two distinct SerpinA1 isoform profiles. Interpretation: CJD
linked to PrPSc type 1 and FTLD show a differential upregulation and
post-translational modifications of CSF SerpinA1. Further studies are needed to
clarify whether these findings may reflect a common, albeit disease-specific,
pathogenetic mechanism related to neurodegeneration.
Introduction
SerpinA1, also known as alpha-1 antitrypsin, is an acute
inflammatory protein belonging to the superfamily of ser-
pins, which acts as a serine protease inhibitor. With the
exception of liver and blood cells, its expression is strictly
downregulated throughout the body, including the brain.1
Nonetheless, several pieces of evidence suggest that Ser-
pinA1 may play a role in neurodegeneration. In this
regard, overexpression of the protein or its RNA has been
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described in the brains of patients with Alzheimer’s dis-
ease (AD)2 and frontotemporal lobar degeneration
(FTLD),1 suggesting that SerpinA1 overexpression may be
detrimental to neuronal function.1 Moreover, the protein
may play an anti-inflammatory role by attenuating micro-
glial activation, causing a reduction of neuroinflamma-
tion.3–5 It is also known that the protein might diffuse
out of venous blood and be released from the brain tissue
into the cerebrospinal fluid (CSF).6 Previous studies doc-
umented a higher concentration of CSF SerpinA1 and/or
different levels of its charge isoforms in AD, Parkinson’s
disease (PD), Parkinson’s disease dementia (PDD), and
dementia with Lewy bodies in comparison with con-
trols.6–9 However, to date, no studies specifically investi-
gated CSF SerpinA1 isoforms in Creutzfeldt–Jakob disease
(CJD) and FTLD, with the exception of a preliminary
study in the latter.9
CJD and FTLD are highly heterogeneous neurodegener-
ative diseases from the clinical, genetic, and neuropatho-
logical points of view. CJD includes six major
clinicopathological subtypes that are largely determined
by the genotype at the methionine (M)/valine (V) poly-
morphic codon 129 of the PRNP gene and the type (1 or
2) of disease-associated prion protein (PrPSc) accumulat-
ing in the brain.10 At variance, phenotypic heterogeneity
in FTLD spectrum is mainly related to two major pro-
teinopathies, namely FTLD with TDP43 (FTLD-TDP) and
tau pathology (FTLD-TAU).11
To further study the role of SerpinA1 in neurodegener-
ative disorders, we tested CSF SerpinA1 in controls and
patients with a definite or probable diagnosis of CJD and
FTLD subtypes. To this aim, we took advantage of our
previously developed capillary isoelectric focusing (CIEF)
immunoassay for the analysis of SerpinA1.6 Moreover, we
evaluated the possible correlations between SerpinA1,
clinical variables, and the levels of currently established
biomarkers of neurodegeneration.
Methods
Inclusion criteria and case classification
CSF samples were submitted for analysis to the Neu-
ropathology Laboratory at the Institute of Neurological
Sciences of Bologna (Italy) or to the Neurology Department
of Ulm University Hospital (Germany) between 2010 and
2018. The cohort comprised 31 healthy controls, 77
patients with CJD, and 30 with FTLD. The study was con-
ducted according to the revised Declaration of Helsinki and
Good Clinical Practice guidelines. Informed consent was
given by study participants or by their next of kin. The
present study was approved by the ethics committees of
“Area Vasta Emilia Centro” and Ulm University.
Classification of sporadic CJD (sCJD) was made
according to the newly proposed criteria for CJD and
related disorders (http://www.cjd.ed.ac.uk/sites/default/file
s/criteria_0.pdf). Specifically, the group of “definite” prion
disease consisted of 52 prion-positive cases at postmortem
examination (27 sCJD MM(V)1, 13 VV2, 9 MV2K, 2
MM2C, and 1 VV1) and 5 cases carrying a pathogenic
PRNP mutation [5 genetic CJD with E200K-129M haplo-
type (gCJD E200K-129M)] whereas the group of “proba-
ble” sCJD included 18 patients fulfilling the clinical
criteria for possible sCJD and showing a positive prion
real-time quaking-induced conversion (RT-QuIC) assay.
Molecular analysis of the PRNP gene, PrPSc typing, and
CJD histotype classification were performed according to
established methodologies and consensus criteria.12–14 In
autopsied cases of CJD (n = 52), which were selected
from a previous study,15 the assessment of AD copathol-
ogy, performed according to the ABC score,16 showed
either the absence or low level or AD-related pathology in
all but two cases demonstrating an intermediate level.
Furthermore, there was no difference in the distribution
of the severity of AD copathology among sCJD subtypes.
For the analysis according to the sCJD molecular sub-
types, we merged the subjects with definite sCJD MM(V)
1, VV2, MV2K, MM2C, and VV112 with those with a
probable sCJD diagnosis and a high level of certainty for
a given subtype (7 probable VV2, 11 probable MV2K,
and 2 probable MM2C). In detail, the classification was
determined by the consensus of two consultant neurolo-
gists (SAR and PP) after reviewing typical clinical fea-
tures, disease duration at death or at last at follow-up,
the results of codon 129 genotype (MM, MV, and VV),
CSF biomarkers, and brain magnetic resonance imaging
(supplementary methods of Appendix S1). However, to
exclude a bias related to possible misdiagnosis, we also
analyzed the data after the exclusion of probable cases.
The FTLD group comprised cases with a pathological
and/or genetic diagnosis of FTLD-TDP (n = 24) or
FTLD-TAU (n = 6) as previously described.17 Specifically,
the FTLD-TDP group included patients with (1) a patho-
logical diagnosis of TDP43 subtype B pathology (n = 1);
(2) a pathogenic mutation in chromosome 9 open read-
ing frame 72 gene (C9orf72) (n = 16, including the one
with pathological diagnosis), progranulin (GRN) (n = 7),
and TAR DNA-binding protein 43 gene (TARDBP)
(n = 1). Otherwise, the FTLD-TAU group included
patients with (1) a pathological diagnosis of primary
tauopathy (1 progressive supranuclear palsy, 1 corti-
cobasal degeneration) and (2) a pathogenic mutation in
microtubule-associated protein tau gene (MAPT) (n = 4).
In all FTLD cases, the in vivo evidence of AD pathology
was gathered using the AD core CSF biomarkers and
in-house calculated cutoff ratios.18 Specifically, a
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phosphorylated (p)-tau/amyloid-b (Ab)42 ratio >0.108
(Bologna)17 or >0.08 (Ulm) was considered supportive
for AD.
The control group included 31 subjects lacking any
clinical or neuroradiologic evidence of central nervous
system disease and having all three biomarkers total (t)-
tau, p-tau and Ab42 in the normal range.19
CSF biochemical analysis
In both centers, CSF samples were obtained by lumbar
puncture (LP) at the L3/L4 or L4/L5 level following a
standard procedure. All samples were centrifuged (multiple
times in case of blood contamination); the supernatant was
divided into aliquots and stored in polypropylene tubes at
80°C until analysis. Given the use of different tubes for
storage in the two centers, we performed a SerpinA1
absorption property test. We could not detect significant
differences in SerpinA1 signals for the same three samples
aliquoted in two distinct storage tubes (data not shown).
Furthermore, all samples were at maximum 3 times frozen
and thawed. A previous stability analysis with samples four
times frozen and thawed found no loss in signal intensity.6
For SerpinA1, each CSF sample was measured in duplicate.
The mean intra-assay coefficient of variation (CV) was
3.45% and the mean interassay CV 7.11% (calculated by
repeating the analysis of two samples in four different
runs). The CV of repeatability (two samples analyzed in
one run in three different cycles) was 9.02%. The CSF
SerpinA1 analysis was performed using a CIEF immuno-
assay platform (NanoPro 1000, ProteinSimple, Santa Clara,
USA) as previously described.6 The reagents for the assay
including pH gradient, fluorescent standards, capillaries
were directly obtained from ProteinSimple. As primary
antibody, a monoclonal mouse anti-human SerpinA1 anti-
body was bought from R&D Systems (MAB1268, Min-
neapolis, USA).
CSF neurofilament light-chain protein (NfL), t-tau, p-tau
and Ab42 were analyzed using commercially available
enzyme-linked immunosorbent assay kits (NF-light, IBL,
Hamburg, Germany; INNOTEST htau-Ag, INNOTEST
phosphorylated-Tau181, INNOTEST Ab1–42, Innogenetics/
Fujirebio Europe, Ghent, Belgium) as previously described.20
PrPSc seeding activity was detected by RT-QuIC as previ-
ously described.13 The mean intra- and interassays coeffi-
cients of variation (CVs) were ≤5% and ≤11%, respectively,
for t-tau and NfL as previously reported.20
Statistical analysis
Statistical analysis was performed using IBM SPSS Statis-
tics version 21 (IBM, Armonk, NY) and GraphPad Prism
7 (GraphPad Software, La Jolla, CA) software. Based on
the presence or not of a normal distribution of the values,
data were expressed as mean  standard deviation (SD)
or median and interquartile range (IQR). For continuous
variables, depending on the data distribution, the Mann–
Whitney U test or the t test was used to test differences
between two groups, while the Kruskal–Wallis test (fol-
lowed by Dunn–Bonferroni’s post hoc test) or the one-
way analysis of variance (followed by Tukey’s post hoc
test) was applied for multiple group comparisons. Chi-
square test was adopted for categorical variables. Spear-
man’s correlations were used to test the possible associa-
tions between analyzed variables. All reported P-values
have been adjusted for multiple comparison analyses. Dif-
ferences were considered statistically significant at
P < 0.05.
Results
Demographics and CSF biomarker results in
the diagnostic groups
Demographic data concerning the diagnostic groups are
shown in Table 1. There were no significant differences
regarding age and sex distribution among patient groups.
As expected, the time interval between onset and LP was
significantly shorter in subjects with CJD than in those
with FTLD (P < 0.001). Indeed, due to the frequent suba-
cute onset and rapid progression, the former are usually
evaluated early after the onset of symptoms. Times from
onset to LP were 1.99  1.82, 3.38  1.16,7.66  6.40,
13.25  8.5 and 10 months for MM(V)1, VV2, MV2K,
MM2C, and VV1 groups, respectively. Statistically signifi-
cant differences were found between MM(V)1 and MV2K
(P < 0.001) or VV2 (P < 0.001) groups and between
MV2K and VV2 groups (P = 0.042). CSF t-tau and NfL
values for each group are shown in Table 1.
Distribution of CSF SerpinA1 isoforms
across diagnostic groups
In all cases and independently from the disease group or
subtype, we found at least six distinct SerpinA1 peaks
with isoelectric points (pI) ranging from 4.3 to 4.7 (peaks
1–6). Moreover, we observed a seventh peak on the acidic
side (peak 0) in several samples with CJD or FTLD
pathology, as previously described for PDD6 (Fig. 1).
For the evaluation of CIEF electropherograms, we cal-
culated semiquantitatively the peak areas by analyzing the
signal intensities for each SerpinA1 isoform individually
and for total SerpinA1 as the sum of single peaks. We
analyzed the following variables: (1) absolute area of total
SerpinA1, calculated as the summed area of all peaks and
(2) normalized area values, consisting of the ratio
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between the single peak area and the summed-up area of
all peaks as previously described.6
The overall SerpinA1 signal was significantly higher in
FTLD cases compared to controls (P = 0.002), although no
differences were detected between CJD and controls or
FTLD (Fig. 2A). After stratification according to the three
most representative sCJD molecular subtypes [MM(V)1,
VV2, and MV2K], we detected a significant difference
between controls and sCJD MM(V)1 (P = 0.026) but not
between controls and the VV2 or MV2K groups (Fig. 2B).
Similarly, CJD types linked to PrPSc type 1 [sCJD MM(V)1,
VV1, and gCJD E200K-129M] showed higher SerpinA1
total area compared to controls (P = 0.007) and cases asso-
ciated with PrPSc type 2 (VV2, MV2K, and MM2C)
(P = 0.014), whereas the values in the latter group were
similar to those of the controls. Moreover, while the total
area was significantly higher in the FTLD-TDP group com-
pared to controls (P = 0.005), the FTLD-TAU group
showed only a tendency toward an increased value
(P = 0.02; adjusted post hoc P = 0.06), which is possibly
explained by the small sample size (Fig. 2C).
In addition, the three diagnostic groups differed in the
relative abundance of several charge isoforms (Fig. 3A).
Specifically, in controls the most intense peak (peak 3)
had a pI between 4.5 and 4.6 (controls vs. FTLD
P = 0.010; controls vs. CJD P = 0.031), while the iso-
forms on its acidic and basic sides were less abundant. At
variance, the CJD and FTLD groups were characterized
by a relative increase of acidic (peak 0: P = 0.001; peak 1:
P = 0.024) and basic isoforms (peak 6: P = 0.028) respec-
tively in comparison with the controls (Fig. 3B–D). While
the normalized areas of peak 4 and 5 were similar in the
three diagnostic groups, the signals of peaks 2
(P = 0.029) and 6 (P = 0.007) differed between CJD and
FTLD (Fig. 3D).
After stratification according to the CJD molecular sub-
type, we found that the differences between CJD and con-
trols in single peak signals on the acidic side were driven
by the MM(V)1 group (peak 0: P < 0.0001; peak 1:
P = 0.006). Indeed, no differences in normalized areas
were detected between VV2 and MV2K groups and con-
trols (Fig. 4A). Similarly, electropherogram morphology
in the few sCJD MM2C cases (Fig. 1C) resembled that of
controls and VV2/MV2K cases (Fig. 1A and B), whereas
in the single VV1 patient (Fig. 1E) looked similar to that
of the MM(V)1 group (Fig. 1D). Indeed, the subanalysis
based on PrPSc types confirmed that CJD cases linked to
PrPSc type 1 showed different normalized areas of indi-
vidual peaks on the acidic side compared to controls
(peak 0: P < 0.001; peak 1: P = 0.002) and CJD linked to
PrPSc type 2 (peak 0: P = 0.002; peak 1: P = 0.049). In
addition, gCJD E200K-129M and VV2 patients showed
values of both total and normalized peak areas compara-
ble, respectively, to those of the sCJD MM(V)1 and the
MV2K groups. All the analyses after exclusion of probable
sCJD cases confirmed the same findings (supplementary
results of Appendix S1). In contrast, the relative increase
of peak 6 in the FTLD group compared to controls was
associated with the FTLD-TAU group (P = 0.028) but
not with FTLD-TDP (Fig. 4B). Distinct FTLD genetic
subgroups did not differ in both total area and single
peak areas.
In both the CJD (even when limited to the single
molecular subtypes) and the FTLD groups, there were no
associations between age, time from onset to LP, t-tau,
NfL, and SerpinA1 total area. Further details regarding
correlations between time from onset to LP and SerpinA1
variables in the CJD group are illustrated in supplemen-
tary results of Appendix S1.
Discussion
The results of the present study demonstrated that Ser-
pinA1 is highly expressed in the CSF of patients with CJD
linked to PrPSc type 1 and in a subgroup of those of the
FTLD spectrum. Moreover, different isoform patterns of
SerpinA1 characterize specific CJD and FTLD subtypes, as
previously shown for AD, PDD, and PD.6–9
Table 1. Demographic and biochemical data in the diagnostic groups.
Diagnosis CJD FTLD Controls
N 77 30 31
Age at LP (years SD) 66.14  7.78 63.19  7.66 64.87  9.85
Female (%) 48.1% 53.3% 47.2%
Time from onset to LP (months  SD)1 4.50  3.01 38.68  35.00 –
t-tau (pg/mL) Median (IQR)2 4262 (2037–9173) 307 (221–430) 167 (136–227)
NfL (pg/mL) Median (IQR)3 8785 (4242–12225) 4644 (3000–7075) 601 (421–807)
1CJD versus FTLD P < 0.001.
2CJD versus controls P < 0.001; CJD versus FTLD P < 0.001.
3CJD versus controls P < 0.001; CJD versus FTLD P = 0.029; FTLD versus controls P < 0.001.
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The role of upregulated and post-translationally modi-
fied SerpinA1 in neurodegeneration remains speculative.
While protein abnormal post-translational phosphorylation
and glycosylation are recognized as pathogenetic mecha-
nisms in neurodegenerative disorders,6 sialylation modifi-
cations have been less frequently reported, with SerpinA1
being one of the exceptions.9 On the one hand, SerpinA1
may play a protective role as a molecular chaperone that
prevents amyloid fibril formation21 and its O-linked sialyla-
tion could act as a suppressor of pathogenetic self-hyper-
phosphorylation as sialylation and phosphorylation share
similar motifs.6,22 Alternatively, SerpinA1 post-translational
modifications might be detrimental by (1) blocking specific
serine proteases and lead to impaired clearance of prion-
like proteins23 or (2) promoting the formation of a mis-
folded and self-aggregate-prone structure of SerpinA1.9,21
On another issue, SerpinA1 is emerging as an important
modulator of neuroinflammation.3–5
Independently from the hypothetical roles of SerpinA1,
it seems that a different isoform-overexpression character-
izes some of the CJD and FTLD subtypes. On the other
hand, the preservation of the most abundant peak
(number 3) in controls could suggest a possible critical
physiological role of this isoform.
Figure 1. Typical CSF electropherograms of SerpinA1 isoforms. The y-axis depicts the signal in arbitrary units; the x-axis the isoelectric point
(pI). (A) Overlay of a sCJD VV2 (pink) and a control (green) electropherogram. (B) Overlay of a sCJD MV2K (rose) and a control (green)
electropherogram. (C) Overlay of a sCJD MM2C (purple) and a control (green) electropherogram. (D) Overlay of a sCJD MM(V)1 (red) and a
control electropherogram (green). At variance with the VV2, MV2K, and MM2C profiles, the MM(V)1 electropherogram differs from the control
one. Seven [MM(V)1] or six (control) distinct peaks around the pI of 4.5 were detected. Most notably is the difference in the abundance of the
acidic isoforms. (E) Overlay of a sCJD VV1 (orange) and a control (green) electropherogram, showing, in the former, the same increase of the
acidic isoforms detected in the MM(V)1 cases. (F) Overlay of a FTLD (blue) and a control (green) electropherogram. In the case of FTLD, the
most significant difference is in the abundance of the two most basic isoforms. CJD, Creutzfeldt–Jakob disease; FTLD, frontotemporal lobar
degeneration; MM(V)1, methionine homozygosity (valine) and disease-associated prion protein type 1; MM2C, methionine homozygosity and
disease-associated prion protein type 2; MV2K, methionine–valine heterozygosity and disease-associated prion protein type 2; sCJD, sporadic
Creutzfeldt–Jakob disease; VV1, valine homozygosity and disease-associated prion protein type 1; VV2, valine homozygosity and disease-
associated prion protein type 2.
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Figure 2. Results of absolute peak area analysis. (A) Comparison of the total absolute area of the three main cohorts (controls, CJD, FTLD). (B)
Comparison between controls and sCJD patients after stratification into sCJD subtypes. (C) Comparison between controls and FTLD patients after
stratification into the two FTLD subtypes. Box plots show median concentrations with 25% and 75% percentiles and Tukey whiskers. *P < 0.05,
**P < 0.01. CJD, Creutzfeldt–Jakob disease; Con, controls; CU, chemiluminescence unit; FTLD, frontotemporal lobar degeneration; FTLD-TAU,
frontotemporal lobar degeneration with tau pathology; FTLD-TDP, frontotemporal lobar degeneration with TDP43 pathology; MM(V)1, methionine
homozygosity (valine) and disease-associated prion protein type 1; MV2K, methionine/valine heterozygosity and disease-associated prion protein
type 2; sCJD, sporadic Creutzfeldt–Jakob disease; VV2, valine homozygosity and disease-associated prion protein type 2.
Figure 3. Results of relative peak area analysis. (A) Comparison of mean relative peak areas of all seven peaks of the three main cohorts
(controls, CJD, FTLD). Error bars indicate SEM. (B) Normalized area results for peak 0. (C) Normalized area results for peak 3. (D) Normalized area
results for peak 6. Symbols in B, C, and D indicate mean normalized area of peak 0, 3, and 6, respectively. Error bars show the 95% confidence
interval. *P < 0.05, **P < 0.01. CJD, Creutzfeldt–Jakob disease; Cons, control; FTLD, frontotemporal lobar degeneration.
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Most interestingly, CJD cases linked to PrPSc type 1,
such as sCJD MM(V)1, VV1, and gCJD E200K-129M
types, differed in total and single peak area from both
controls and cases linked to PrPSc type 2 (VV2, MV2K,
and MM2C groups). It is well established that the type of
PrPSc largely determines the distinctive histopathological
and molecular features of sCJD.24 In this respect, the dif-
ferent post-translational modifications of SerpinA1
between sCJD subtypes may represent a PrPSc-specific or
a strain pathogenetic event. Accordingly, the lack of dif-
ference in SerpinA1 profile between sCJD MM(V)1 and
gCJD E200K-129M or between sCJD VV2 and sCJD
MV2K are consistent with the notion that these couples
of prion variants are, respectively, linked to the same
PrPSc type and strain.25 Another possible hypothesis could
relate the different SerpinA1 patterns to the kinetics of
the disease even if we did not find significant associations
between the time from onset to LP and SerpinA1 signal
in each CJD molecular subgroup. Moreover, given that
SerpinA1 might play an anti-inflammatory role by attenu-
ating microglial activity,3–5 the increase in total SerpinA1
and in some of its isoforms in sCJD MM(V)1 compared
to sCJD linked to PrPSc type 2 could be considered a
stronger early attempt to balance the developing neuroin-
flammation/neurodegeneration that progresses faster in
the former group than in the latter. Possibly, SerpinA1
immunomodulation may attenuate during the slower
disease course in VV2, MV2K, and MM2C cases. In this
regard, a higher severity/amount of activated microglia
has been described in the sCJD VV2 compared to the
MM(V)1 subtype.26 Further studies which correlate Ser-
pinA1 levels with the microglial load in CJD brain tissues
and the kinetics of the pathology could clarify the role of
SerpinA1 in the pathogenesis of prion disease.
On another issue, the difference in SerpinA1 between
PrPSc type 1 and 2 CJD cases could be helpful to distin-
guish in vivo PrPSc types. However, the partial overlap in
SerpinA1 levels and electropherogram profiles and the
limited diagnostic accuracy (data not shown) represent a
limit to its application at the individual level.
Similarly, in FTLD the highly expressed isoform corre-
sponding to peak 6 seems to be a characteristic of the
TAU group, even if this finding needs to be validated in a
larger cohort. Thus, we speculate that the wide pathologi-
cal heterogeneity in both CJD and FTLD could reflect a
different expression of SerpinA1 isoforms. Accordingly, all
the mentioned isoform patterns were different from those
previously described by us in PD and PDD.6
On another issue, recent studies showed that SerpinA3,
another member of the serpin family, is significantly
upregulated in brains and CSF of patients with prion dis-
ease, both at the mRNA and at the protein level, although
to a different extent for each pathological subtype.23,27,28
However, all these studies focused on the levels of total
Figure 4. Relative peak area analysis for sCJD and FTLD subtypes. (A) Normalized peak area analysis of peak 0 for the sCJD subgroups. (B)
Normalized peak area analysis of peak 6 for the FTLD subgroups. Box plots show median concentrations with 25% and 75% percentiles and
Tukey whiskers. *P < 0.05, ****P < 0.0001. Con, controls; FTLD, frontotemporal lobar degeneration; FTLD-TAU, frontotemporal lobar
degeneration with tau pathology; FTLD-TDP, frontotemporal lobar degeneration with TDP43 pathology; MM(V)1, methionine homozygosity
(valine) and disease-associated prion protein type 1; MV2K, methionine/valine heterozygosity and disease-associated prion protein type 2; sCJD,
sporadic Creutzfeldt–Jakob disease; VV2, valine homozygosity and disease-associated prion protein type 2.
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protein but did not evaluate isoforms with a very sensi-
tive assay such as CIEF.
The major strength of our study is the inclusion of dis-
ease cases with certainty or high level of probability in
predicting the underlying neuropathology (e.g., autopsy-
proven, genetic, and RT-QuIC-positive cases). In the pre-
sent study, we did not investigate SerpinA1 isoforms with
CIEF in brain tissue of our autopsy-verified cases, due to
the potential infective load of sCJD samples. As another
limitation, we included only a few sporadic cases of
FTLD, and so our findings might need confirmation in
other cohorts of pathologically proven sporadic FTLD.
Finally, the effect of preanalytical variables (e.g., tube
material) deserves further investigations, if quantitative
assays for the measurement of SerpinA1 should be devel-
oped in the future.
Taking our findings and previous data together, we
speculate that upregulation and post-translational modifi-
cations of SerpinA1, and to a large extent of all serpin
proteins, could be common features of most neurodegen-
erative disorders. Nevertheless, further studies on experi-
mental models and in other neurodegenerative disorders
(e.g., amyotrophic lateral sclerosis, Huntington’s disease)
are needed to clarify the specific functions of SerpinA1
and other members of the serpin family in neurodegener-
ation. In detail, studies in mouse and cell models in
which SerpinA1 expression might be up- or downregu-
lated will be helpful to investigate whether SerpinA1
could drive or mitigate the pathological hallmarks
through the modulation of neuroinflammation in distinct
CJD and FTLD subtypes, or whether its dysregulation is
only one of several downstream effects of the underlying
cause.
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